scholarly journals Tri-functional platform for construction of modular antibody fragments for in vivo18F-PET or NIRF molecular imaging

2020 ◽  
Vol 11 (7) ◽  
pp. 1832-1838
Author(s):  
Raymond F. Gamache ◽  
Kirstin A. Zettlitz ◽  
Wen-Ting K. Tsai ◽  
Jeffrey Collins ◽  
Anna M. Wu ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Optical Imaging ◽  
Targeted Delivery ◽  
Antibody Fragments ◽  
Imaging Agents ◽  
Universal Approach

To provide a universal approach towards the targeted delivery of PET and optical imaging agents, we have developed a tri-functional platform (TFP) for the facile construction of modular, target-specific tracers.

Molecular Imaging of Inflammation/Infection: Nuclear Medicine and Optical Imaging Agents and Methods

2010 ◽  
Vol 110 (5) ◽  
pp. 3112-3145 ◽  
Author(s):  
A. Signore ◽  
S. J. Mather ◽  
G. Piaggio ◽  
G. Malviya ◽  
R. A. Dierckx
Keyword(s):  
Nuclear Medicine ◽  
Molecular Imaging ◽  
Optical Imaging ◽  
Imaging Agents

scholarly journals A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors

2020 ◽  
Vol 13 (8) ◽  
pp. 199
Author(s):  
Joseph Lau ◽  
Julie Rousseau ◽  
Daniel Kwon ◽  
François Bénard ◽  
Kuo-Shyan Lin
Keyword(s):  
Molecular Imaging ◽  
Smooth Muscle Contraction ◽  
Therapeutic Interventions ◽  
Imaging Agents ◽  
Kinin System ◽  
Normal Tissues ◽  
Molecular Imaging Agents ◽  
Inflammatory State ◽  
B2 Receptors ◽  
Tissue Trauma

Kinins, bradykinin and kallidin are vasoactive peptides that signal through the bradykinin B1 and B2 receptors (B1R and B2R). B2R is constitutively expressed in healthy tissues and mediates responses such as vasodilation, fluid balance and retention, smooth muscle contraction, and algesia, while B1R is absent in normal tissues and is induced by tissue trauma or inflammation. B2R is activated by kinins, while B1R is activated by kinins that lack the C-terminal arginine residue. Perturbations of the kinin system have been implicated in inflammation, chronic pain, vasculopathy, neuropathy, obesity, diabetes, and cancer. In general, excess activation and signaling of the kinin system lead to a pro-inflammatory state. Depending on the disease context, agonism or antagonism of the bradykinin receptors have been considered as therapeutic options. In this review, we summarize molecular imaging agents targeting these G protein-coupled receptors, including optical and radioactive probes that have been used to interrogate B1R/B2R expression at the cellular and anatomical levels, respectively. Several of these preclinical agents, described herein, have the potential to guide therapeutic interventions for these receptors.

scholarly journals Single Chain Variable Fragment Fused to Maltose Binding Protein: A Modular Nanocarrier Platform for the Targeted Delivery of Antitumorals

2021 ◽  
Author(s):  
Francisco J. Reche-Perez ◽  
Simona Plesselova ◽  
Eduardo De los Reyes-Berbel ◽  
Mariano Ortega-Muñoz ◽  
F. Javier Lopez-Jaramillo ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Targeted Delivery ◽  
Specific Binding ◽  
Protein A ◽  
Antibody Fragments ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Binding Properties ◽  
Single Chain Variable Fragments ◽  
Selective Delivery

The use of the specific binding properties of monoclonal antibody fragments such as single-chain variable fragments (ScFv) for the selective delivery of antitumor therapeutics for cancer cells is attractive due...

Investigations into porphyrins as potential molecular imaging agents

2010 ◽  
Vol 37 (6) ◽  
pp. 689
Author(s):  
Philip Alan Waghorn ◽  
Jon R. Dilworth*
Keyword(s):  
Molecular Imaging ◽  
Imaging Agents ◽  
Molecular Imaging Agents

scholarly journals Recommendations for reporting on emerging optical imaging agents to promote clinical approval

Theranostics ◽  
2018 ◽  
Vol 8 (19) ◽  
pp. 5336-5347 ◽  
Author(s):  
Willemieke S. Tummers ◽  
Jason M Warram ◽  
Nynke S. van den Berg ◽  
Sarah E. Miller ◽  
Rutger-Jan Swijnenburg ◽  
...  
Keyword(s):  
Optical Imaging ◽  
Imaging Agents

scholarly journals Gold Nanoparticle-Based Fluorescent Theranostics for Real-Time Image-Guided Assessment of DNA Damage and Repair

2019 ◽  
Vol 20 (3) ◽  
pp. 471 ◽  
Author(s):  
Shriya S. Srinivasan ◽  
Rajesh Seenivasan ◽  
Allison Condie ◽  
Stanton L. Gerson ◽  
Yanming Wang ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Real Time ◽  
Targeted Delivery ◽  
Specific Binding ◽  
Imaging Techniques ◽  
Cancer Cell Line ◽  
Molecular Probe ◽  
Biodistribution Studies

Chemotherapeutic dosing, is largely based on the tolerance levels of toxicity today. Molecular imaging strategies can be leveraged to quantify DNA cytotoxicity and thereby serve as a theranostic tool to improve the efficacy of treatments. Methoxyamine-modified cyanine-7 (Cy7MX) is a molecular probe which binds to apurinic/apyrimidinic (AP)-sites, inhibiting DNA-repair mechanisms implicated by cytotoxic chemotherapies. Herein, we loaded (Cy7MX) onto polyethylene glycol-coated gold nanoparticles (AuNP) to selectively and stably deliver the molecular probe intravenously to tumors. We optimized the properties of Cy7MX-loaded AuNPs using optical spectroscopy and tested the delivery mechanism and binding affinity using the DLD1 colon cancer cell line in vitro. A 10:1 ratio of Cy7MX-AuNPs demonstrated a strong AP site-specific binding and the cumulative release profile demonstrated 97% release within 12 min from a polar to a nonpolar environment. We further demonstrated targeted delivery using imaging and biodistribution studies in vivo in an xenografted mouse model. This work lays a foundation for the development of real-time molecular imaging techniques that are poised to yield quantitative measures of the efficacy and temporal profile of cytotoxic chemotherapies.

scholarly journals Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases

Antibodies ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 27 ◽  
Author(s):  
Kasandra Bélanger ◽  
Umar Iqbal ◽  
Jamshid Tanha ◽  
Roger MacKenzie ◽  
Maria Moreno ◽  
...  
Keyword(s):  
Inflammatory Diseases ◽  
Building Blocks ◽  
Structural Features ◽  
Antibody Fragments ◽  
Single Domain ◽  
Imaging Agents ◽  
Cns Diseases ◽  
Single Domain Antibodies ◽  
Potential Therapeutics ◽  
Brain Barriers

Antibodies have become one of the most successful therapeutics for a number of oncology and inflammatory diseases. So far, central nervous system (CNS) indications have missed out on the antibody revolution, while they remain ‘hidden’ behind several hard to breach barriers. Among the various antibody modalities, single-domain antibodies (sdAbs) may hold the ‘key’ to unlocking the access of antibody therapies to CNS diseases. The unique structural features of sdAbs make them the smallest monomeric antibody fragments suitable for molecular targeting. These features are of particular importance when developing antibodies as modular building blocks for engineering CNS-targeting therapeutics and imaging agents. In this review, we first introduce the characteristic properties of sdAbs compared to traditional antibodies. We then present recent advances in the development of sdAbs as potential therapeutics across brain barriers, including their use for the delivery of biologics across the blood–brain and blood–cerebrospinal fluid (CSF) barriers, treatment of neurodegenerative diseases and molecular imaging of brain targets.

Sign in / Sign up

Export Citation Format

Share Document